140 results about "Kidney disorder" patented technology

The embodiment of the invention discloses a model optimization method based on transfer learning. The method comprises the following steps: acquiring to-be-migrated learning data, wherein the to-be-migrated learning data comprises source domain data associated with pathological characteristics of kidney diseases; semantic alignment processing is carried out on the source domain data and target domain data, the target domain data is kidney disease pathology data, and a semantic alignment result is obtained; determining a feature distribution result corresponding to the target domain data, and determining a migration weight corresponding to the source domain data based on the feature distribution result and the semantic alignment result; and optimizing the target domain model based on the migration weight, the source domain data and the target domain data to obtain an optimized target domain model. According to the embodiment of the invention, the accuracy and robustness of the target domain model in a kidney disease pathological diagnosis task and the generalization ability of different data distributions can be remarkably improved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

To simply provide information showing a degree of a kidney disease of a feline animal.SOLUTION: A urine inspection system includes a storage part and a control part. The storage part stores kidney disease information on a relation between a level of a D-amino acid in urine of a feline animal and a degree of a kidney disease of the feline animal. The control part receives D-amino acid information showing the level of the D-amino acid in the urine from the feline animal from a user terminal belonging to an owner or an inspection institute of the feline animal. Then, the control part estimates the degree of the kidney disease of the feline animal on the basis of the received D-amino acid information and the kidney disease information and transmits kidney disease degree information showing the estimated degree of the kidney disease to the user terminal.SELECTED DRAWING: Figure 4

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention discloses application of Htr2b and an inhibitor thereof in prevention or treatment of chronic kidney diseases, provides application of Htr2b as a drug target in screening of drugs for prevention or treatment of chronic kidney diseases, and further provides application of the inhibitor of Htr2b in preparation of drugs for prevention or treatment of chronic kidney diseases. It is found that after the Htr2b function of DIO mice is inhibited, kidney injury caused by high fat is obviously relieved, the Htr2b inhibitor can inhibit important inflammatory factors MCP-1, IL-1, IL-6 and TNF-alpha and ectopic lipid deposition of the chronic kidney diseases, renal function markers of creatinine, urea nitrogen and UACR of the DIO mice can be obviously reduced, and the Htr2b inhibitor has the obvious effect of preventing or treating the chronic kidney diseases and has a good application prospect. The compound can be used for preparing medicines for preventing or treating chronic kidney diseases.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

The present invention relates to a benzene-containing polycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in general formula (I-1), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of a drug for treating diabetes, obesity, NASH, renal diseases and diseases associated therewith, wherein each substituent in general formula (I-1) is the same as that defined in the specification.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The invention discloses lactobacillus mucilaginosus, a microbial agent and application, and belongs to the technical field of microorganisms. The lactobacillus mucus is fermentation lactobacillus mucus and / or lactobacillus reuteri, the fermentation lactobacillus mucus is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34245, the preservation date is April 17, 2025, and the preservation number is AIML-C0029; the lactobacillus reuteri is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.34601, the preservation date is May 20, 2025, and the lactobacillus reuteri is named as AIML-C0053. The lactobacillus mucilaginosus can be applied to preparation of medicines for treating and / or preventing renal edema and kidney injury, and a new thought is provided for treating or preventing kidney diseases.

The application discloses a traditional Chinese medicine composition for regulating inflammation-oxidative stress-bone metabolism axis and application thereof, and belongs to the field of kidney disease treatment. The traditional Chinese medicine composition is composed of Herba Epimedii, Rhizoma Drynariae, Radix Eucommiae, Radix Rehmanniae Preparata, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Flos Carthami, Radix Salviae Miltiorrhizae, Olibanum, Poria, Rhizoma Atractylodis Macrocephalae, Radix Trichosanthis, Radix Clematidis, Caulis Spatholobi and Radix Glycyrrhizae. The composition can be prepared into pharmaceutically acceptable dosage forms such as granules, granules for oral taking, capsules, tablets, pills, oral liquid or ointments. The traditional Chinese medicine composition has the characteristics of sustained curative effect, good safety and comprehensive regulation of multiple targets, and can be used for preparing drugs for regulating inflammation-oxidative stress-bone metabolism axis, improving mineral and bone metabolism abnormalities of chronic kidney disease and treating chronic musculoskeletal pain of patients with maintenance hemodialysis.

The present disclosure relates to apoptosis-induced stem cells, a method for producing the same, and a pharmaceutical composition for the prevention or treatment of an inflammatory disease or a renal disease, including the same. Cells according to an aspect and a composition including the cells as an active ingredient have an increased IL-10 expression level without including a cryoprotectant, and thus can be effectively used for the prevention or treatment of an inflammatory disease or a renal disease.

The application belongs to the field of biological detection, and particularly relates to a technology and a reagent for detecting NAG by a VRA-NAG substrate method. The linear range of the NAG detection reagent provided by the application can reach (0, 500] U / L; within the range, when the anti-acid is less than or equal to 340 micromoles / L, urea is less than or equal to 42.9 millimoles / L, uric acid is less than or equal to 1.4 millimoles / L, albumin is less than or equal to 100 milligrams / dL, bilirubin is less than or equal to 342 micromoles / L, lactic acid is less than or equal to 6.6 millimoles / L, glucose is less than or equal to 55 millimoles / L, triglyceride is less than or equal to 37 millimoles / L, and oxalic acid is less than or equal to 81 micromoles / L, these components have no obvious interference on the test. Moreover, the relative standard deviation caused by the accelerated aging of the detection reagent for 10 days is not more than ±10%. Compared with the prior art, the kit provided by the application has high sensitivity, wide linear range, strong specificity and good stability, and is conducive to early detection and early treatment of kidney diseases in clinical practice.

The application belongs to the technical field of kidney disease differential diagnosis, and particularly relates to a microbial gene marker for differentiating diabetic nephropathy and membranous nephropathy and application thereof. The application provides sufficient evidence for the differentiation and treatment of clinical diagnosis of diabetic nephropathy and pathological diagnosis of membranous nephropathy based on four microbial markers of Blautia, Akkermansia, Sphingomonas and Granulicatella.

The present disclosure provides methods for treating a subject with renal disease or preventing a subject from developing renal disease, as well as methods for identifying a subject at increased risk for developing renal disease, by administering an angiopoietin-like 3 (ANGPTL3) inhibitor and a solute carrier family 5 member 2 (SLC5A2) inhibitor.

According to the application of the PDE4DIP serving as the biomarker in preparation of the reagent kit for adjuvant therapy of the kidney podocyte injury and the podocytosis, the reagent kit comprises a reagent for detecting the PDE4DIP, and in a word, it is confirmed for the first time that the expression of the PDE4DIP can be reduced under the conditions of the kidney podocyte injury and the podocytosis; on one hand, the invention provides the application of the PDE4DIP transcription factor or the functional fragment thereof as a target spot for improving the renal podocyte injury and the podocytosis, and on the other hand, the invention provides the new application of the PDE4DIP as a biomarker (pathological diagnosis) in the diagnosis of the renal podocyte injury and the podocytosis renal injury. The invention solves the blank of no specific targeted treatment tool in the field of kidney diseases, discovers the new application of the PDE4DIP as a biomarker in the treatment of kidney podocyte injury and podocytosis, provides a specific verification method and experimental data, and has very positive significance.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

This invention discloses a reactive oxygen species (ROS)-responsive nanocomposite for targeting and repairing damaged endothelium, its preparation, and its application, belonging to the field of nanomedicine technology. The nanocomposite comprises a physalicylate-copper nanoparticle core and a P-selectin-targeting polypeptide linked to the core surface via thiol-copper affinity. The physalicylate-copper nanoparticle core is prepared by coordination of physalicylate and copper ions to form a primary complex, followed by ascorbic acid reduction. This composite nanosystem can specifically recognize and accumulate in the blood vessels and peritubular regions of the kidney injury area, releasing Cu in response to high concentrations of ROS in an inflammatory environment. 2+ Together with HBT, it simultaneously achieves antioxidant and anti-inflammatory functions, promotes angiogenesis and repair, and inhibits the release of inflammatory factors and macrophage infiltration and activation, effectively blocking the fibrosis process. This system has a well-defined structure and strong targeting, and can effectively rebuild microvessels, reduce inflammation, and block the process of renal fibrosis, providing a highly efficient and precise new nanomedicine strategy for the anti-fibrotic treatment of kidney diseases.

The present invention relates to use of an aromatic biological antagonist in preparing a medicament for treating or preventing a kidney disease. Specifically, the present invention provides use of 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl-d2)-N-(4-chloro-5-methylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'- biphenyl]-2-sulfonamide compound or a pharmaceutically acceptable salt thereof in preparing a medicament for treating or preventing a kidney disease, especially in preparing a medicament for treating or preventing focal segmental glomerulosclerosis and immunoglobulin A nephropathy. The compound or the pharmaceutically acceptable salt thereof shows excellent therapeutic effects on focal segmental glomerulosclerosis and immunoglobulin A nephropathy, and has great clinical application prospects.

The present invention relates to a carboxyl-containing heterocyclic derivative modulator, a preparation method therefor, and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of a drug for treating diabetes, obesity, NASH, renal diseases, and related conditions thereof, wherein each substituent in general formula (I) is as defined in the description.

The present invention relates to novel compounds of general Formula I with multifaceted pharmacological activities. The compounds of the invention exhibit SGLT1, SGLT2, and DPP4 inhibition. The present invention also provides processes and intermediates to obtain the compounds of the invention, pharmaceutical compositions comprising encompasses the compounds, processes and intermediates for the synthesis of the compounds, pharmaceutical compositions, combinations, medicaments, therapeutical uses and methods for the treatment of diseases, for instance, cardiovascular and renal diseases, including heart failure, chronic kidney disease, diabetes mellitus, diabetic nephropathy and myocardial infarction. [Chem. 1] Compound of Formula I (I)

The application discloses a preparation method of a tubular epithelial cell-targeted anti-oxidative peptide and application thereof, and specifically comprises the following steps: 1) first, N-Boc protected serine (Ser) is dissolved in N,N-dimethylformamide (DMF), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) are sequentially added, stirring is carried out at room temperature for 2-4 hours to obtain an active ester solution; 2) polypeptide CTGFVAVR is added into the active ester solution, stirring is continuously carried out at room temperature for 2-4 hours, trifluoroacetic acid (TFA) is added after the reaction is completed, and a reaction product is purified to obtain a tubular epithelial cell-targeted anti-oxidative peptide. The prepared Ser-CTG can break through the double bottleneck of targeting efficiency and curative effect in AKI treatment, provides technical support for the precise medical development of kidney diseases, and has significant clinical transformation value and market application prospect.

The application discloses application of benzoyl oxypaeoniflorin in preparation of a medicine for preventing or treating FABP4 high-expression related kidney diseases. It is found for the first time that the benzoyl oxypaeoniflorin can effectively prevent or treat FABP4 high-expression related kidney diseases, especially renal interstitial fibrosis, by inhibiting a FABP4 target.

Disclosed herein are methods of treating compliment mediated diseases using a crosslinked poly(allyamine) polymer comprising the residues of 2-propen-1-ylamine, or a salt thereof, 1,3-bis(allylamino)propane, or a salt thereof, and 1,2-dichloroethane.

The invention relates to the technical field of organoid culture, in particular to a construction method and application of a kidney organoid model. Comprising the following steps: S1, carrying out digestion and flow sorting on renal cortex tissues to obtain renal stem cells; s2, carrying out plane culture on the kidney stem cells to obtain kidney epithelial progenitor cells; s3, performing three-dimensional culture on the renal epithelial progenitor cells to obtain the kidney organ model. According to the method, an adult renal cortex tissue is taken as a starting cell source, a kidney organ model with mature near-end and far-end renal tubule phenotypes is efficiently constructed through an optimized plane amplification and three-dimensional induction culture system, and the formation of kidney organs can be efficiently induced in a short time; the finally obtained kidney organ model can be used for simulating acute kidney injury in vitro, and an efficient tool is provided for kidney disease mechanism research, drug toxicity screening and personalized treatment model construction.

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.